Testosterone or Primobolan: What Is the Difference

Primobolan is the trade name of methenolone, a derivative of dihydrotestosterone that was produced both in tablets and in injections. It is often called a "mild" steroid, contrasted with testosterone. The editorial team examines what the real chemical and pharmacological differences are and what follows from them for health.

A brief characterization of the two substances

Testosterone is a natural androgen and at the same time a medicinal product used for replacement therapy in hypogonadism. Its pharmacology and safety within physiological levels are the best studied among all androgens.

Methenolone was synthesized by the pharmaceutical company Schering in the early 1960s. It was produced in two forms: methenolone acetate for oral use and methenolone enanthate for intramuscular injections (Primobolan Depot). It was used mainly for anemias associated with bone marrow insufficiency and for wasting conditions.

Today registered methenolone products are unavailable or restricted in most countries. There are practically no clinical studies meeting modern standards, so most knowledge about it is last-century pharmacology and doping-analysis data.

So in this comparison too we deal with an asymmetry: on one side, a modern medicinal product with clinical guidelines; on the other, a substance with a limited modern evidence base.

Chemistry: why methenolone needs a methyl group at position 1

Methenolone is 1-methyl-5α-androst-1-en-17β-ol-3-one. More simply, it is a DHT molecule with two changes: a double bond between the first and second carbon atoms and a methyl group at the first position.

Most oral anabolic steroids have a methyl group at position 17α. It protects the molecule from breakdown in the liver during first pass, but it is precisely this that is associated with pronounced hepatotoxicity: cholestasis, peliosis hepatis, tumors.

Methenolone took a different path: it has no 17α-alkylation. Instead, the modification at position 1 gives the molecule a certain stability. Because of this, methenolone acetate is considered less hepatotoxic than methylated tablets, although it also has significantly lower bioavailability when taken orally.

Testosterone, by contrast, has a conventional structure with a double bond at position 4. As a free hormone it is of little use orally, as it is rapidly broken down by the liver. That is why it is used in injections, gels, or as a special oral undecanoate form that is absorbed through the lymphatic system.

Oral and injectable forms

The existence of a tablet form is one of the reasons for primobolan's popularity. However, the oral route has an obvious drawback: a considerable part of the substance is broken down in the liver, and to achieve an effect larger amounts are needed than with injections.

The injectable enanthate is released slowly from the oil depot, similarly to testosterone enanthate. The difference between them lies not in the ester but in the active molecule itself that is released after it is cleaved off.

In modern medicine testosterone has more administration options, including transdermal gels that give more stable hormone levels without peak fluctuations. No such forms existed for methenolone.

Regardless of form, both substances suppress the pituitary's production of gonadotropins. The widespread notion that tablets "do not suppress" one's own hormone does not correspond to pharmacology: any androgen in a sufficient amount activates the negative feedback mechanism.

Aromatization, DHT, and tissue effects

Like other DHT derivatives, methenolone is not a substrate for aromatase. It does not form estradiol, so estrogenic effects — gynecomastia, fluid retention — are not characteristic of it. Testosterone, on the contrary, is partly converted into estradiol.

Methenolone is also not converted by 5α-reductase, since it already has the 5α configuration. In the skin, hair follicles, and prostate, testosterone is converted into DHT, which enhances androgenic effects in these tissues.

Because of these features methenolone is traditionally considered a drug with moderate androgenicity. But it must be remembered that it has androgenic effects on its own too, as an androgen receptor agonist. Acne, alopecia, and virilization in women are possible.

The absence of aromatization has a downside too. If, against a background of suppression of one's own testosterone, the body has no other source of estrogens, a deficiency of them is possible, with effects on the bones, libido, and lipid metabolism.

Finally, the anabolic potency of methenolone, according to available estimates, is moderate. That is precisely why informal sources describe it as "mild," but mildness of effect is not equivalent to safety.

Comparison of risks

Most serious risks are shared by both substances and by the entire class of anabolic-androgenic steroids. The Endocrine Society scientific statement (2014) systematizes them as follows:

• suppression of the hypothalamic-pituitary-gonadal axis with a risk of prolonged hypogonadism and impaired fertility;
• reduced HDL and increased LDL;
• cardiomyopathy, arrhythmias, accelerated atherosclerosis;
• psychiatric effects: irritability, aggressiveness, depression during withdrawal, formation of dependence;
• virilization in women.

A specific difference of methenolone is the risks associated with oral use. Although it is not 17α-alkylated, any oral androgen affects the synthesis of lipoproteins in the liver more than an injectable one.

A specific difference of testosterone is estrogenic effects and the effect of DHT on the prostate. In medical practice they are controlled through monitoring of hematocrit, PSA, and symptoms.

And again — product quality. Pharmaceutical primobolan is rare and expensive, so on the illegal market it is often counterfeited. Samples of products sold as methenolone have repeatedly contained other substances.

Editorial conclusions

Testosterone and primobolan (methenolone) belong to different families of androgens. Methenolone is a DHT derivative that does not aromatize, is not converted by 5α-reductase, and has an oral form without 17α-alkylation.

These chemical features change the profile of side effects but do not remove the main risks of the class: suppression of the hormonal axis, dyslipidemia, and strain on the heart.

Testosterone remains the only one of the two substances with modern medical indications and controlled quality.

We also recommend reading our materials on the hepatotoxicity of oral steroids, on the classification of androgens by parent molecule, and on the tests for monitoring the lipid profile.

References

1. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502–521.
2. Schänzer W. Metabolism of anabolic androgenic steroids. Clin Chem. 1996;42(7):1001–1020.
3. Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
4. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
5. Nieschlag E, Behre HM, Nieschlag S (eds). Testosterone: Action, Deficiency, Substitution. 4th ed. Cambridge University Press; 2012.
6. Handelsman DJ. Androgen physiology, pharmacology, use and misuse. In: Feingold KR, et al., eds. Endotext. South Dartmouth (MA): MDText.com.
7. World Anti-Doping Agency. The Prohibited List. International Standard. Montreal: WADA; 2025.